JMT103: What should count as an answer?
An editorial reading of trial endpoints, reported outcomes, and the questions to ask before discussing a development opportunity.
THE HIVEPROSPECT WEEKLY
Good stories. Better questions.
Drug discoveries, difficult failures and the business decisions between them.
Filed under JMT103 · Clear filter